These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 35961703)

  • 21. Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    Liu Y; Zhuo S; Zhou Y; Ma L; Sun Z; Wu X; Wang XW; Gao B; Yang Y
    J Hepatol; 2022 Mar; 76(3):652-664. PubMed ID: 34793870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
    Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
    Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.
    Kodaka M; Hata Y
    Cell Mol Life Sci; 2015 Jan; 72(2):285-306. PubMed ID: 25266986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. YAP and the Hippo pathway in cholangiocarcinoma.
    Sugihara T; Isomoto H; Gores G; Smoot R
    J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M
    J Hepatol; 2024 Aug; 81(2):265-277. PubMed ID: 38508240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hippo pathway effectors YAP, TAZ and TEAD are associated with EMT master regulators ZEB, Snail and with aggressive phenotype in phyllodes breast tumors.
    Akrida I; Makrygianni M; Nikou S; Mulita F; Bravou V; Papadaki H
    Pathol Res Pract; 2024 Oct; 262():155551. PubMed ID: 39153238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Hill MA; Alexander WB; Guo B; Kato Y; Patra K; O'Dell MR; McCall MN; Whitney-Miller CL; Bardeesy N; Hezel AF
    Cancer Res; 2018 Aug; 78(16):4445-4451. PubMed ID: 29871934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
    Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review).
    Li S; Hao L; Li N; Hu X; Yan H; Dai E; Shi X
    Int J Oncol; 2024 Sep; 65(3):. PubMed ID: 39092548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
    Yang L; Niu K; Wang J; Shen W; Jiang R; Liu L; Song W; Wang X; Zhang X; Zhang R; Wei D; Fan M; Jia L; Tao K
    J Hepatol; 2024 Oct; 81(4):651-666. PubMed ID: 38679071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
    Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
    Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
    Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
    Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matricellular proteins in intrahepatic cholangiocarcinoma.
    Sirica AE
    Adv Cancer Res; 2022; 156():249-281. PubMed ID: 35961702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
    Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
    J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
    Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
    Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
    Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
    J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.